

2019

medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



MEDICINA

Volumen 79, Supl. IV, págs. 1-338

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina
José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina
Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina
Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina
Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Rodolfo S. Martín
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina
Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina
Rodolfo C. Pucho
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina
Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina
Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina
Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Argentina
Christiane Dosne Pasqualini
Academia Nacional de Medicina, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: Fundación Revista Medicina

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,

1427 Buenos Aires, Argentina

Tel. 5287-3827 Int. 73919 y 4523-6619

e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina
de Ciencia y Tecnología de Animales de Laboratorio
(AACyTAL)**

**con la participación de
The Histochemical Society**

13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

ANNUAL MEETING OF BIOSCIENCE SOCIETIES 2019

**LXIV Annual Meeting of
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Annual Meeting of
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Annual Meeting of
Sociedad Argentina de Biología (SAB)**

**XXXI Annual Meeting of
Sociedad Argentina de Protozoología (SAP)**

**IX Annual Meeting of
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Regional Scientific Meeting of Asociación Argentina
de Ciencia y Tecnología de Animales de Laboratorio
(AACyTAL)**

**with the participation of
The Histochemical Society**

November 13th – 16th, 2019
Hotel 13 de Julio - Mar del Plata

CHIEF EDITORS

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

This assay was positive for DNA from *Leishmania guyanensis*, *L. mayori*, *L. amazonensis*, *L. braziliensis* and *L. infantum*. LAMP was negative for *Toxoplasma gondii* and *Trypanosoma rangeli*. The detection limit was 1.0×10^2 parasites/mL. This assay was positive also in 10 specimens obtained by lesion's biopsy. The advantages of this novel tool include the speed with which the assays can be completed, the no-need of trained personnel, and the fact that it can be performed without complex and expensive laboratory equipment.

0874 - IFN- γ INDUCTION BY THE TC13TUL ANTIGEN FROM TRYPANOSOMA CRUZI IN NAÏVE BALB/C MICE

Laura Mónica TASSO | Patricia Andrea GARAVAGLIA | Monica Ines ESTEVA | Andrea Cecilia BRUBALLA | Maria Cecilia ALBAREDA | Gabriela Andrea GARCIA

INSTITUTO NACIONAL DE PARASITOLOGÍA "DR MARIO FATALA-CHABEN" ANLIS MALBRAN; CONICET

Trypanosoma cruzi, the etiological agent of Chagas disease, releases factors which modulate the host immune responses, including Tc13 antigens. Regarding innate immune responses, Tc13 antigen from Tulahuén strain, Tc13Tul, has shown to induce B cell expansion and non-specific IgM production on cultures of splenocytes from naïve BALB/c mice. To obtain further information about this role, we evaluated Tc13Tul ability to induce cytokine secretion by in vitro and in vivo stimulation. In vitro Tc13Tul stimulation of splenocytes from naïve BALB/c mice induced higher IFN- γ secretion than that induced by the control protein MBP (554 ± 140 pg/ml and 35.33 ± 18.56 pg/ml, respectively). Differences in neither IL-17 nor IL-4 were detected. Tc13Tul-induced IFN- γ secretion was also observed in cultured naïve splenocytes from the LPS-resistant C3H/HeJ mouse strain. In vivo administration of Tc13Tul (or MBP as control) to naïve BALB/c mice (3 daily ip doses of 1 μ g/mouse/dose) increased non-specific IgG in sera. In addition, in vitro cultured splenocytes from Tc13Tul-inoculated mice secreted a higher basal level of non-specific IgM than controls and the in vitro Tc13Tul stimulation of these cells showed an additive effect on IgM secretion. Regarding Tc13Tul-induced IFN- γ secretion, in vitro cultured splenocytes from Tc13Tul-inoculated mice have no differences in basal levels respect to controls; however, when splenocytes were in vitro stimulated with Tc13Tul, cells from Tc13Tul-inoculated mice showed higher IFN- γ secretion than cells from MBP-inoculated mice (950 ± 265.2 pg/ml and 147.3 ± 55.48 pg/ml, respectively). Results indicate that Tc13Tul participation in the innate immune response against *T. cruzi* is mainly exerted in phenomena related to the evasion of the immune system, such as non-specific Ig production. In contrast, as IFN- γ is an important factor involved in *T. cruzi* resistance, this may be considered a Tc13Tul effect in favor to the host.

0876 - VACCINE STRATEGIES AGAINST BABESIA BIGEMINA BASED ON PRIME-BOOST IMMUNIZATIONS IN MICE WITH RECOMBINANT PROTEINS AND MODIFIED VACCINIA ANKARA VECTOR

Valeria MONTENEGRO | José JARAMILLO ORTIZ | Martina PAOLETTA | María José GRAVISACO | Sofía DE LA FOURNIÈRE | Magalí VALENZANO | Paula DEL MÉDICO ZAJAC | Gabriela CALAMANTE | Silvina WILKOWSKY

INTA

Babesia bigemina is an apicomplexan tick-borne parasite that infects RBC causing cattle morbidity and mortality in vast world areas. Vaccination with attenuated strains is effective but they have inherent disadvantages. Immunity to *Babesia* sp. requires both innate and adaptive responses including CD4+ T cells and neutralizing antibodies. The aim of this study was to evaluate prime-boost heterologous schemes in mice using immunogens that activate both humoral and cellular responses. Three recombinant

proteins and two modified vaccinia virus Ankara (MVA) expressing a chimeric multi-antigen were obtained and evaluated as vaccines. The multi-antigen comprises B and T cell epitopes of the *B. bigemina* proteins: AMA-1, RAP-1 and TRAP-1. Epitope prediction was performed by bioinformatics using the *B. bigemina* genome. Mice were immunized at day 0 with recombinant proteins and at day 30 with each MVA. One group received a prime of AMA-1, RAP-1 and TRAP-1 in equal amounts and 30 days after alpha-MVA (containing epitopes of AMA-1 and RAP-1) and beta-MVA (containing epitopes of TRAP-1). A second group received a prime of AMA-1 and RAP-1 and a boost of alpha-MVA. A third group was immunized with recombinant TRAP-1 and then with beta-MVA. Two control groups received either a heterologous protein and wt-MVA or vehicle only. Serum samples were collected for antibody analysis and spleen cells were obtained at day 60 for cellular and cytokines assays. Priming with a cocktail of the 3 antigens and a boost with alpha-MVA and beta-MVA induced the highest level of specific IgG antibodies and activation of IFN- γ CD4+ and CD8+ specific T cells. This group also showed a high ratio (>1) of IgG2a to IgG1 for the recombinant proteins AMA-1 and RAP-1 suggesting a strong induction of Th1-biased response. In summary, we have shown that a three-protein cocktail and both MVA used in prime-boost regimes are immunogenic for both antibodies and CD8+ /CD4+ T cells generating promising levels of B and T cell mediated immunity.

0890 - FINDING OF FASCIOLA HEPATICA IN A CAPYBARA (HYDROCHAERIS HYDROCHAERIS) IN TANDIL, PROVINCE OF BUENOS AIRES, ARGENTINA

María Victoria SOLANA | Silvana SCARCELLA | Hugo SOLANA

CIVETAN CONICET

Fasciolosis is a zoonotic parasitic disease caused by *Fasciola hepatica*. The life cycle of this parasite is indirect, it needs a snail of the Lymnaea family as an intermediate host to complete the cycle and so the occurrence of cases is limited to the presence of these snails. Most of the studies of this parasitic disease are in domestic animals and humans. Great economic losses are generated by this disease. Wild species are known to act as reservoirs and disseminators of the disease. The south-eastern zone of the province of Buenos Aires has been described with reference to the presence of *Fasciola* spp. in cattle but it is not yet known whether wild herbivores living in the zone are involved in the biological cycle of this disease. Among the wild species that have been positively reported to *Fasciola hepatica* the capybara, (*Hydrochaeris hydrochaeris*) is a poorly described species. In August of the present year, in the district of Tandil (Bs. As.), a dead capybara recently run over was found. At the macroscopic inspection the liver was apparently normal. At the magnifying glass inspection of the gall bladder, characteristic yellowish eggs were found. They were photographed with the Leica microscope and it can be seen that due to their morphology, size and location they were compatible with *Fasciola hepatica* eggs. PCR was performed in search of the mitochondrial gene ITS1 (species indicator) confirming that the eggs found in the capybara belonged to *Fasciola hepatica*. This is attractive for two main reasons; first, in the area where the animal was found there are no scientific reports of this disease or the presence of the snail, which prompts us to work on a more exhaustive search for cases. And secondly, the study of wild species as transmitters of this disease is not well studied and this ends up being a complication for producers and for the population in general, so we consider that its study is very important.

0897 - IN VITRO EVALUATION OF THE ANTIMICROBIAL EFFECT OF EXTRA VIRGIN OLIVE OIL (EVOO) AND OF THE ACTIVE COMPOUNDS HYDROXYTYLSOL AND OLEUROPEIN AGAINST HELICOBACTER PYLORI.